FDA grants approval for Simplera Sync sensor compatible with MiniMed 780G insulin pump
Medtronic's MiniMed 780G System with Simplera Sync Sensor: A Game-Changer in Diabetes Management
Medtronic, a global leader in medical technology, has announced the integration of the Simplera Sync sensor with its MiniMed 780G system. This development promises to revolutionize diabetes management by offering improved glucose monitoring and automated insulin delivery.
The Simplera Sync sensor, FDA-approved for use with the MiniMed 780G system, provides a reliable and compatible continuous glucose monitoring (CGM) solution. This sensor is disposable, all-in-one, and requires no fingersticks, SmartGuard, or overtape, making it user-friendly and convenient.
The MiniMed 780G system, already renowned for its Meal Detection technology, now offers more flexibility with the addition of the Simplera Sync sensor. This system features an infusion set that lasts up to 7 days, requiring only one change per week.
When paired with the MiniMed 780G’s adaptive algorithm, the Simplera Sync sensor helps users maintain better blood glucose levels with fewer highs and lows. Real-time glucose monitoring and alerts enable the system to automatically adjust insulin delivery every few minutes, helping to maintain glucose within target ranges and prevent hypoglycemia or hyperglycemia.
This integration helps decrease the cognitive load and stress involved in diabetes management by automating insulin dosing based on sensor data, thus easing daily decision-making related to meals and insulin adjustments. The sensor offers more flexibility for users in diabetes management, likely featuring improved wearability, sensor life, and accuracy compared to previous sensors.
In addition, the CGM technology, including systems like MiniMed 780G with such sensors, often supports remote data sharing with caregivers or healthcare providers to provide additional safety and peace of mind.
The MiniMed 780G system's adaptive algorithm adjusts glucose levels every 5 minutes, 24/7, and uses a "treat to target" approach and flexible glucose targets as low as 100 mg/dL. Real-world data shows global users consistently achieve time in range above international targets of 70% when using optimal settings with the MiniMed 780G system.
In conclusion, the Simplera Sync sensor enhances the MiniMed 780G system by providing accurate, real-time glucose data to its automated insulin delivery algorithm. This combination improves glycemic control, reduces user burden, supports safety through alerts and alarms, and offers greater management flexibility for people with diabetes.
The limited launch of the Simplera Sync sensor in the U.S. is scheduled for fall 2025. Que Dallara, EVP and president of Medtronic Diabetes, stated that the company is committed to driving innovation for those living with diabetes. This latest development reaffirms Medtronic's dedication to improving lives through advanced technology.
The integration of the Simplera Sync sensor with Medtronic's MiniMed 780G system signifies a significant leap in the digital health sector, bridging the gap between science and medical-conditions related to diabetes management. This health-and-wellness advancement is expected to redefine the user experience by offering real-time glucose monitoring, automated insulin delivery, and improved wearability for those living with diabetes.
